Revised SPC: Keytruda (pembrolizumab) 50 mg powder for concentrate for solution for infusion

Sjogren’s syndrome has been added as an adverse event (frequency rare for monotherapy and in combination with chemotherapy and uncommon in combination with axitinib).

Source:

electronic Medicines compendium